BioCryst Pharmaceuticals, Inc. (BCRX)
8.01
-0.16
(-1.96%)
USD |
NASDAQ |
Oct 05, 09:53
BioCryst Pharmaceuticals EPS Diluted (Quarterly) : 0.2957 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2957 |
| March 31, 2026 | -2.980 |
| December 31, 2025 | 1.121 |
| September 30, 2025 | 0.0587 |
| June 30, 2025 | 0.0231 |
| March 31, 2025 | 0.0001 |
| December 31, 2024 | -0.1292 |
| September 30, 2024 | -0.0678 |
| June 30, 2024 | -0.0614 |
| March 31, 2024 | -0.1717 |
| December 31, 2023 | -0.3065 |
| September 30, 2023 | -0.1906 |
| June 30, 2023 | -0.3983 |
| March 31, 2023 | -0.2829 |
| December 31, 2022 | -0.3827 |
| September 30, 2022 | -0.2284 |
| June 30, 2022 | -0.3171 |
| March 31, 2022 | -0.4013 |
| December 31, 2021 | -0.0978 |
| September 30, 2021 | -0.3283 |
| June 30, 2021 | -0.243 |
| March 31, 2021 | -0.3615 |
| December 31, 2020 | -0.3425 |
| September 30, 2020 | -0.2612 |
| June 30, 2020 | -0.239 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.2439 |
| December 31, 2019 | -0.02 |
| September 30, 2019 | -0.3405 |
| June 30, 2019 | -0.341 |
| March 31, 2019 | -0.2819 |
| December 31, 2018 | -0.2498 |
| September 30, 2018 | -0.2808 |
| June 30, 2018 | -0.19 |
| March 31, 2018 | -0.2614 |
| December 31, 2017 | -0.20 |
| September 30, 2017 | -0.18 |
| June 30, 2017 | -0.21 |
| March 31, 2017 | -0.1892 |
| December 31, 2016 | -0.06 |
| September 30, 2016 | -0.16 |
| June 30, 2016 | -0.22 |
| March 31, 2016 | -0.31 |
| December 31, 2015 | -0.25 |
| September 30, 2015 | -0.20 |
| June 30, 2015 | 0.06 |
| March 31, 2015 | -0.21 |
| December 31, 2014 | -0.16 |
| September 30, 2014 | -0.12 |
| June 30, 2014 | -0.23 |
| March 31, 2014 | -0.17 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Amgen, Inc. | 4.366 |
| Halozyme Therapeutics, Inc. | 1.897 |
| Neurocrine Biosciences, Inc. | 1.386 |
| Vertex Pharmaceuticals, Inc. | 4.310 |
| Agenus, Inc. | -0.0146 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 78.40M |
| Revenue (Quarterly) | 218.25M |
| Total Expenses (Quarterly) | 139.86M |
| Enterprise Value | 2.569B |
| Gross Profit Margin (Quarterly) | 98.01% |
| Profit Margin (Quarterly) | 35.92% |
| Earnings Yield | -18.78% |
| Operating Earnings Yield | 20.29% |
| Normalized Earnings Yield | 6.971 |